Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0000899243-20-017761)

Filing Details

Accession Number:: 0000899243-20-017761
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-06-26 16:17:31
Reporting Period:: 2020-06-25

Accepted Time:: 2020-06-26 16:17:31
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1680581	Fulcrum Therapeutics Inc.	FULC	Pharmaceutical Preparations (2834)	474839948

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1778713	Diego Cadavid	C/O Fulcrum Therapeutics, Inc. 26 Landsdowne Street Cambridge MA 02139	Svp Clinical Development	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-06-25	1,459	$4.83	68,244	No	4	M	Direct
Common Stock	Disposition	2020-06-25	1,459	$22.00	66,785	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2020-06-25	1,459	$0.00	1,459	$4.83

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
12,277		2028-07-10	No	4	M	Direct

Footnotes

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019.
The shares underlying the option are scheduled to vest in equal quarterly installments from July 16, 2018 through July 15, 2022.